Casebia Therapeutics, a joint venture between Bayer and CRISPR Therapeutics, has hired new laboratory and office space in Cambridge, Massachusetts, USA, for its primary research operations. The facilities are located in a new building which is currently under construction adjacent to the Massachusetts Institute of Technology’s (MIT) campus in Kendall Square.

Casebia will be co-located with CRISPR Therapeutics and plans are for the company to move in early next year. Currently, research efforts are being performed at the various R&D sites of Bayer and CRISPR Therapeutics in Germany and the US. An additional location on Bayer’s campus in Mission Bay, San Francisco, will house research operations in hematology indications.

CRISPR Therapeutics, headquartered in Basle, Switzerland, with R&D operations in Cambridge, Massachusetts, finalized its JV with Bayer in the first quarter of 2016. The partners aim to develop new breakthrough therapies for blood disorders, blindness and congenital disease using CRISPR’s gene-editing technology. Last October, CRISPR Therapeutics announced a separate collaboration with Vertex Pharmaceuticals focused on cystic fibrosis and sickle cell anemia.